arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

LIXT
$7.29 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
21 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

LIXTE BIOTECHNOLOGY HOLDINGS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -41.8% ↗
FCF / Share None
Trailing P/E —
Price / Book 6.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Jul 2, 2026.

21-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$200.00K
— —
Net Income Profit after all expenses
$-6.08M
↓ -69.5% —
FCF / Share Free cash flow per share
$-2.24
↑ +23.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns →
14
Financial Health ↑
6
Cash Quality ↓
40

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 21 years · 81 quarters